Literature DB >> 21567277

[Parameters to improve the specificity of the prostate-specific antigen. Early detection of prostate cancer].

C Börgermann1, S Kliner, A Swoboda, H-J Luboldt, H Rübben.   

Abstract

PURPOSE: The aim of the study was to improve the case detection rate of prostate cancer for patients who had unremarkable palpation findings and a PSA value in the range of 4 to 10 ng/ml by combination of the parameters total PSA (tPSA), f/tPSA ratio, prostate volume, PSA density, patient's age and transrectal ultrasound findings.
METHODS: Sextant biopsy of the prostate was performed for 619 patients aged 45-75 years who had unremarkable palpation findings and PSA values in the range of 4 to 10 ng/ml. The f/tPSA ratio was determined, transrectal ultrasound examination was performed, the prostate volume was measured and the PSA density calculated. The relationship between the various test variables - and their combination - and the histology results was investigated using logistic regression.
RESULTS: Prostate cancer was detected in 131 of 619 patients. Analysis of the aforementioned test variables by means of logistic regression revealed that the combination of the parameters f/tPSA ratio, PSA density and patient's age can significantly increase the sensitivity and specificity of PSA in predicting prostate cancer compared with the use of these parameters on an individual basis. With an assumed limit value of 5% for performance of punch biopsy, 31% of biopsies could be avoided in practice. In such a case, only 3% of instances of prostate cancer would have gone undetected.
CONCLUSION: The combined use of f/tPSA ratio, PSA density and patient's age can significantly enhance the case detection sensitivity for the PSA range of 4 to 10 ng/ml.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567277     DOI: 10.1007/s00120-011-2577-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  29 in total

Review 1.  The value of current diagnostic tests in prostate cancer screening.

Authors:  I W Van Der Cruijsen-Koeter; M F Wildhagen; H J De Koning; F H Schröder
Journal:  BJU Int       Date:  2001-09       Impact factor: 5.588

2.  PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Authors:  Ina L Deras; Sheila M J Aubin; Amy Blase; John R Day; Seongjoon Koo; Alan W Partin; William J Ellis; Leonard S Marks; Yves Fradet; Harry Rittenhouse; Jack Groskopf
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

3.  The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful!

Authors:  C Börgermann; A Swoboda; H-J Luboldt; F vom Dorp; H Rübben
Journal:  World J Urol       Date:  2009-06-28       Impact factor: 4.226

4.  Intra- and inter-observer variability and reliability of prostate volume measurement via two-dimensional and three-dimensional ultrasound imaging.

Authors:  S Tong; H N Cardinal; R F McLoughlin; D B Downey; A Fenster
Journal:  Ultrasound Med Biol       Date:  1998-06       Impact factor: 2.998

5.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

6.  Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination.

Authors:  C G Roehrborn; S Sech; J Montoya; T Rhodes; C J Girman
Journal:  Urology       Date:  2001-06       Impact factor: 2.649

7.  Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.

Authors:  H J Luboldt; A Bex; A Swoboda; J Hüsing; H Rübben
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

8.  [Early detection of prostatic carcinoma in urologic practice with digital rectal examination and prostate-specific antigen. Early Detection Project Group].

Authors:  H J Luboldt; J Hüsing; J E Altwein; K H Bichler; D Czaja; P Fornara; K H Jöckel; K Schalkhäuser; L Weissbach; M Wirth; H Rübben
Journal:  Urologe A       Date:  2000-07       Impact factor: 0.639

9.  Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values.

Authors:  E D Crawford; S Leewansangtong; S Goktas; K Holthaus; M Baier
Journal:  Prostate       Date:  1999-03-01       Impact factor: 4.104

10.  Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.

Authors:  C Mettlin; G P Murphy; F Lee; P J Littrup; A Chesley; R Babaian; R Badalament; R A Kane; F K Mostofi
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

View more
  2 in total

1.  [The results of the European randomized study of screening for prostate cancer (ERSPC) 2012: confirmation or disappointment?].

Authors:  C Schaefer; L Weissbach
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

Review 2.  Characterization of disease-associated N-linked glycoproteins.

Authors:  Yuan Tian; Hui Zhang
Journal:  Proteomics       Date:  2013-02       Impact factor: 3.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.